论文部分内容阅读
中国仿制性药物之所以独领风骚,是有其历史与现实原因的。其中决定性的因素,一是人口众多,为了解决大多数人求医问药问题,中国制药产业侧重于非专利性仿制药物生产,尽管药品产量不断增多,但盈利不多;二是开发新药成本过大,不是一般企业所能承受。尽管为数不少的研发机构在一些相当前沿的领域确定项目时期待迥异,但投入不足使积极性多少被抑制了。总体上,国内企业投入研发的经费通常保持在企业整体资金投入的1％至2％,而西方成熟的制药企业投入研发的费用要占全部投入的15％以上。
The reason why China’s generic drugs dominate lies in its history and reality. Among the decisive factors, one is the large population. In order to solve the majority of people seeking medical treatment and medicine, the Chinese pharmaceutical industry focuses on the production of generic generic drugs. Although the output of pharmaceutical products is constantly increasing, the profitability is small. The second is the cost of developing new drugs Large, not the average business can afford. Although a large number of R & D institutes look very different in identifying projects in some fairly cutting-edge areas, insufficient input has dampened the amount of enthusiasm. In general, the funds invested by domestic enterprises in research and development are usually kept at 1% to 2% of the overall capital investment of the enterprises, while the cost of R & D in mature Western pharmaceuticals accounts for more than 15% of the total investment.